The CYPHER® Sirolimus-Eluting Coronary Stent may reduce re-blockage (restenosis) and the occurrence of major adverse cardiac events in patients with complex coronary artery lesions without increasing the risk of blood clots (thrombosis), according to a new study published in the January 17 issue of the Journal of the American College of Cardiology (JACC).

The SCANDSTENT study (Stenting of Coronary Arteries in Non-Stress/Benestent Disease) is the only randomized study examining the CYPHER® Stent against bare metal stents that includes complex patients, defined as patients with blockages longer than 15 millimeters, side-branch lesions, ostial lesions, and lesions angled at greater than 45 degrees (angulated lesions).

Full Press Release